Home - AOP Orphan

POLYCYTHAEMIA VERA

"I wanted to experience the joy of living, having positive thoughts again.“

Dr. Elena Zagorulko, PV Patient | Head of the MPN Support Group Austria

PULMONARY ARTERIAL HYPERTENSION

"If I had not met her on time, I would not be alive now."

POLYCYTHAEMIA VERA

“I found various means of helping myself and would like to share this experience with other persons.”

NARCOLEPSY WITH OR WITHOUT CATAPLEXY

"The moment, one suspects narcolepsy, the person must be referred to a sleep laboratory."

News

Meet Us Globally

25
Oct.
MPN Advocates
Network Conference

lisbon, portugal
5
Nov.
CPhI
Frankfurt, Germany
11
Nov.
Bio-Europe
Hamburg, Germany

Meet Us in Austria

21
Nov.
Jahrestagung der Österreichischen Parkinsongesellschaft
Vienna, Austria
11
Jan.
ASH Recap
Salzburg, Austria

Science & Innovation

From the Concept to the Drug

AOP Orphan headquarters team in Vienna covers all essential aspects of product development, starting with preclinical research & toxicology, extending to pharmaceutical & clinical development, including regulatory affairs, quality management & pharmacovigilance.

Partnering

Partnering is of key importance for AOP Orphan. It allows further developing AOP Orphan’s rare disease portfolio and enables to approach patients beyond company’s core markets in Europe. Find out more about the cooperation opportunities with AOP Orphan using the link below.

Join AOP Orphan

AOP Orphan team develops, investigates and provides therapy options for patients with rare diseases – commitment and appreciation are the essence of our cooperative work.